Epigenetics: Driving Gynecologic Cancers and Therapies
*Corresponding Author: Dr. Chloe Green, University of Oxford, UK, Email: chloe.green@gmail.comReceived Date: Jun 04, 2025 / Published Date: Jun 30, 2025
Citation: Green DC (2025) Epigenetics: Driving Gynecologic Cancers and Therapies. Current Trends Gynecol Oncol 10: 278
Copyright: 漏 2025 Dr. Chloe Green This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
| Peer-reviewed Full Article 
Abstract
Epigenetic modifications are central to the initiation, progression, and therapeutic resistance of gynecologic cancers. DNA methylation and histone modifications alter gene expression, while ncRNAs are also epigenetically regulated. These changes impact the tumor microenvironment and genomic stability. Emerging epigenetic biomarkers, particularly in ctDNA, aid in early detection. Epigenetic therapies are being developed to reverse aberrant marks and improve treatment outcomes, with a growing emphasis on personalized approaches due to tumor heterogeneity
